drug · small molecule
apatinib mesylate
pre_registrationupdated 3mo agoby Elevar Therapeutics Inc🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for breast cancer and 17 investigational indications.
targets
Vascular endothelial growth factor receptor 2
all catalysts(1)
Trials studying apatinib mesylate
- phase2A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
- phase3Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
- phase3A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
- N/AAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
- phase3Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- phase3A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that